X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Unichem Lab with Sterling Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

UNICHEM LAB vs STERLING BIOTECH - Comparison Results

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    UNICHEM LAB STERLING BIOTECH UNICHEM LAB/
STERLING BIOTECH
 
P/E (TTM) x -276.4 -0.6 - View Chart
P/BV x 2.0 0.0 8,739.0% View Chart
Dividend Yield % 1.3 0.0 -  

Financials

 UNICHEM LAB   STERLING BIOTECH
EQUITY SHARE DATA
    UNICHEM LAB
Mar-17
STERLING BIOTECH
Dec-13
UNICHEM LAB/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs32011 3,046.7%   
Low Rs2213 6,500.0%   
Sales per share (Unadj.) Rs167.226.8 623.7%  
Earnings per share (Unadj.) Rs12.0-15.0 -80.0%  
Cash flow per share (Unadj.) Rs16.9-5.5 -309.9%  
Dividends per share (Unadj.) Rs3.000-  
Dividend yield (eoy) %1.10-  
Book value per share (Unadj.) Rs117.054.9 213.2%  
Shares outstanding (eoy) m90.88267.87 33.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.60.3 623.9%   
Avg P/E ratio x22.6-0.5 -4,867.0%  
P/CF ratio (eoy) x16.0-1.3 -1,255.6%  
Price / Book Value ratio x2.30.1 1,824.8%  
Dividend payout %25.10-   
Avg Mkt Cap Rs m24,5781,862 1,320.2%   
No. of employees `0005.21.4 383.2%   
Total wages/salary Rs m2,487547 454.9%   
Avg. sales/employee Rs Th2,928.35,303.3 55.2%   
Avg. wages/employee Rs Th479.4403.8 118.7%   
Avg. net profit/employee Rs Th209.4-2,959.0 -7.1%   
INCOME DATA
Net Sales Rs m15,1957,181 211.6%  
Other income Rs m11043 258.7%   
Total revenues Rs m15,3057,223 211.9%   
Gross profit Rs m1,788947 188.8%  
Depreciation Rs m4522,543 17.8%   
Interest Rs m344,377 0.8%   
Profit before tax Rs m1,413-5,931 -23.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m326-1,924 -16.9%   
Profit after tax Rs m1,087-4,007 -27.1%  
Gross profit margin %11.813.2 89.2%  
Effective tax rate %23.132.4 71.1%   
Net profit margin %7.2-55.8 -12.8%  
BALANCE SHEET DATA
Current assets Rs m6,42614,335 44.8%   
Current liabilities Rs m3,91749,809 7.9%   
Net working cap to sales %16.5-494.0 -3.3%  
Current ratio x1.60.3 570.0%  
Inventory Days Days68403 16.8%  
Debtors Days Days77171 45.1%  
Net fixed assets Rs m7,41055,432 13.4%   
Share capital Rs m182268 67.9%   
"Free" reserves Rs m10,45413,935 75.0%   
Net worth Rs m10,63614,701 72.3%   
Long term debt Rs m49,478 0.0%   
Total assets Rs m15,25873,988 20.6%  
Interest coverage x42.9-0.4 -12,090.6%   
Debt to equity ratio x00.6 0.1%  
Sales to assets ratio x1.00.1 1,026.2%   
Return on assets %7.30.5 1,466.2%  
Return on equity %10.2-27.3 -37.5%  
Return on capital %13.6-6.4 -211.5%  
Exports to sales %24.125.9 93.1%   
Imports to sales %4.90.2 2,911.3%   
Exports (fob) Rs m3,6661,860 197.1%   
Imports (cif) Rs m75212 6,160.7%   
Fx inflow Rs m5,2981,860 284.9%   
Fx outflow Rs m025 0.0%   
Net fx Rs m5,2981,835 288.8%   
CASH FLOW
From Operations Rs m6831,719 39.8%  
From Investments Rs m-1,316-3,148 41.8%  
From Financial Activity Rs m5921,426 41.5%  
Net Cashflow Rs m-40-3 1,173.5%  

Share Holding

Indian Promoters % 50.1 33.9 147.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 15.1 0.0 -  
FIIs % 3.0 9.9 30.3%  
ADR/GDR % 0.0 16.9 -  
Free float % 31.7 39.3 80.7%  
Shareholders   20,176 21,482 93.9%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare UNICHEM LAB With:   GLENMARK PHARMA  FULFORD INDIA  DR. REDDYS LAB  DIVIS LABORATORIES  ALEMBIC LTD  

Compare UNICHEM LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Lower; Vedanta & Kotak Mahindra Top Losers(Closing)

Indian share markets ended marginally lower on Monday amid weak global cues. The BSE Metal index, however, lost 1.7 amid rising global trade war fears.

Related Views on News

UNICHEM LAB Announces Quarterly Results (4QFY18); Net Profit Down 91.1%

Jun 14, 2018 | Updated on Jun 14, 2018

For the quarter ended March 2018, UNICHEM LAB has posted a net profit of Rs 28 m (down 91.1% YoY). Sales on the other hand came in at Rs 2 bn (down 40.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

Why Bank-Mergers Continue to Remain a Bad Idea(Vivek Kaul's Diary)

Jun 5, 2018

A newsreport suggests that the government plans to merge four public sector banks. We think it's a bad idea.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Jun 18, 2018 03:35 PM

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB 8-QTR ANALYSIS

COMPARE UNICHEM LAB WITH

MARKET STATS